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Abstract
Recent studies have implicated the dying cell as a potential
reservoir of modified autoantigens that might initiate and drive
systemic autoimmunity in susceptible hosts. A number of
subunits of the exosome, a complex of 3'→5' exoribonucleases
that functions in a variety of cellular processes, are recognized
by the so-called anti-PM/Scl autoantibodies, found
predominantly in patients suffering from an overlap syndrome of
myositis and scleroderma. Here we show that one of these
subunits, PM/Scl-75, is cleaved during apoptosis. PM/Scl-75
cleavage is inhibited by several different caspase inhibitors. The
analysis of PM/Scl-75 cleavage by recombinant caspase
proteins shows that PM/Scl-75 is efficiently cleaved by
caspase-1, to a smaller extent by caspase-8, and relatively
inefficiently by caspase-3 and caspase-7. Cleavage of the PM/
Scl-75 protein occurs in the C-terminal part of the protein at
Asp369 (IILD369↓G), and at least a fraction of the resulting N-
terminal fragments of PM/Scl-75 remains associated with the
exosome. Finally, the implications of PM/Scl-75 cleavage for
exosome function and the generation of anti-PM/Scl-75
autoantibodies are discussed.
Introduction
Systemic autoimmune diseases are characterized by the pres-
ence of autoantibodies reactive to a wide variety of autoanti-
gens. Why these autoantibodies, which escape the normal
mechanisms ensuring self tolerance, are made is still not fully
understood. However, the occurrence of modified self-anti-
gens during (either apoptotic or necrotic) cell death in combi-
nation with a defective clearance of dead cells has been
proposed to have a role in the development of autoimmunity
(reviewed in [1,2]). In apoptotic cells many autoantigenic pro-
teins or complexes can be modified by processes such as
(de)phosphorylation, citrullination, nucleolytic cleavage or pro-
teolytic cleavage by caspases (reviewed in [3]). The modifica-
tion and redistribution of these proteins might generate
antigenic determinants to which no tolerance exists, thereby
eliciting a primary immune response. Via epitope spreading,
the initial response, directed to the neo-epitope resulting from
the modification, could evolve to a secondary response in
which antibodies arise that are reactive with other, unmodified
parts of the protein or with proteins that are associated with
the modified antigen [1,4].
Patients suffering from myositis and scleroderma (Scl), which
is called the polymyositis/scleroderma overlap syndrome (PM/
Scl), produce antibodies against a variety of autoantigens.
Some of these are also found in patients suffering from myosi-
tis or scleroderma alone. Autoantibodies recognizing the so-
called PM/Scl autoantigen are found in 24 to 31% of all
patients with PM/Scl [5-8], and in only 2 to 6% of patients suf-
fering from myositis or scleroderma alone [7,9]. Of all patients
positive for anti-PM/Scl antibodies, between 43% and 88%
are diagnosed with a myositis/scleroderma overlap syndromePage 1 of 9
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the yeast exosome, which consists of at least nine core pro-
teins, all displaying exoribonuclease characteristics. The exo-
some has been shown to be involved in the degradation and
processing of many different RNA species [11,12]. Although
the nuclear exosome component PM/Scl-100 and the two
core exosome components PM/Scl-75 and hRrp4p carry the
main autoantigenic epitopes, autoantibodies directed against
PM-Scl-75 seem to be the most prevalent in patients with the
polymyositis/scleroderma overlap syndrome [8]. The cDNA-
derived amino acid sequence for PM/Scl-75 was published in
1991 and is now referred to as PM/Scl-75a-α. A splicing var-
iant of PM/Scl-75a containing an additional exon in the C-ter-
minal region of the protein is known as PM/Scl-75a-β [13].
More recently, we found that the PM/Scl-75a cDNA sequence
is probably incomplete, and identified a PM/Scl-75 cDNA
(referred to as PM/Scl-75c) encoding an additional N-terminal
part that is required for association with the exosome complex
[14].
Until now, none of the subunits of the exosome complex had
been shown to be modified during apoptosis, prompting us to
investigate the molecular characteristics of exosome subunits
in apoptotic cells. Here we demonstrate that the PM/Scl-75
protein is cleaved in a caspase-dependent manner during
apoptosis and that this cleavage occurs in the C-terminal
domain of the protein at residue Asp369.
Materials and methods
Cell lines
Jurkat cells (human T-cell leukemia, ATCC CRL-2570), Peer
cells (human T-cell leukemia) and CCRF-CEM cells (human T-
cell lymphoblastic leukemia, ATCC CCL-119) were grown in
RPMI-1640 medium (Gibco-BRL, Gaithersburg, USA) supple-
mented with 10% heat-inactivated fetal calf serum, 1 mM
sodium pyruvate, penicillin (100 units/ml), and streptomycin
(100 μg/ml). Jurkat cells stably transfected with Bcl-2 (Jurkat/
Bcl-2) or with the empty transfection vector (Jurkat/Neo) were
cultured in the same medium with the addition of 200 μg/ml
G418 (Gibco-BRL).
Induction of cell death
To induce apoptosis, Jurkat cells were treated with the agonis-
tic anti-Fas monoclonal antibody 7C11 as described previ-
ously [15,16]. Peer and CCRF-CEM cells were treated with
0.5 μg/ml actinomycin D, 10 μg/ml anisomycin, 100 μg/ml
cycloheximide or 400 nM staurosporin. CCRF-CEM cells were
also treated with the anti-Fas antibody. The efficiency of apop-
tosis induction was assessed by flow cytometry with the use
of staining with fluorescein isothiocyanate-coupled annexin V
and propidium iodide (PI) as described previously [15]. After
8 hours generally more than 90% of the cells were apoptotic.
After harvesting of the dying cells, cells were washed twice
with phosphate-buffered saline and used immediately or
stored at -70°C. For experiments with the cell-permeable
tetrapeptide caspase inhibitors (Calbiochem, Darmstadt, Ger-
many), Jurkat cells were cultured for 1 hour in the presence of
2 or 20 μM Ac-YVAD-CMK, Z-DEVD-FMK, Z-IETD-FMK or Z-
LEHD-FMK (irreversible inhibitors of caspase-1, caspase-3/-7,
caspase-8 and caspase-9, respectively) as described previ-
ously [16]. The specificity of these inhibitors is based on in
vitro assays with purified caspases. Their specificity in a cellu-
lar context is difficult to define. Subsequently, apoptosis was
induced by the addition of anti-Fas monoclonal antibody fol-
lowed by harvesting the cells after 8 hours of incubation.
Western blot analysis
Cells were lysed on ice for 30 minutes in Nonidet P40 lysis
buffer (25 mM Tris-HCl, pH 7.5, 1% Nonidet P40, 100 mM KCl,
10 mM MgCl2, 1 mM dithiothreitol), containing a protease inhib-
itor cocktail (Complete; Roche, Mannheim, Germany). Cell
lysates were centrifuged for 15 minutes at 4°C (12,000 g) and
the supernatants were used immediately or stored at -70°C.
Protein extracts of 106 cells were analyzed by 10% SDS-PAGE
and Western blotting with systemic lupus erythematosus
patient serum Ven96 (a patient serum reactive with many exo-
some subunits), an anti-PM/Scl-100 rabbit serum [17] or an
anti-PM/Scl-75 rabbit or mouse serum [18], followed by detec-
tion by means of horseradish peroxidase-conjugated secondary
antibodies and visualization by chemiluminescence.
Immunoprecipitation
Protein A–agarose beads (20 μl of 50% slurry) were coated
with 20 μl of Ven96 patient serum, anti-hRrp46p rabbit serum
[17] or anti-PM/Scl-75 [18] rabbit serum. Incubations were
performed overnight at 4°C in IPP500 buffer (500 mM NaCl,
10 mM Tris-HCl, pH 8.0, 0.1% Nonidet P40) by end-over-end
rotation. After the beads had been washed three times with
IPP150 (composition similar to IPP500, but containing 150
mM NaCl), the beads were incubated with 20 μl (2 × 106 cell
equivalents) of Jurkat extract (control or apoptotic) in IPP150
by end-over-end rotation for 2 hours at 4°C. After three wash
steps with IPP150, the beads were resuspended in protein
sample buffer and immunoprecipitated proteins were analysed
by SDS-PAGE and Western blotting.
Plasmids
The cDNAs of PM/Scl-75a-α (GenBank accession number
M58460) and PM/Scl-75c-α (accession number AJ505989)
[14] were cloned into the EcoRI and XbaI sites of the pCI-neo
vector (Promega, Madison, USA), containing an in-frame
vesicular stomatitis virus G epitope (VSV-G) tag at either the
5' end or the 3' end of the cDNAs. For identification of the cas-
pase cleavage site, mutant cDNAs of PM/Scl-75 were gener-
ated, encoding substitution mutants in which one of the
aspartic acid residues at positions 272, 304, 307, 349, 352,
357, 358, 363, 369, 374 and 381 were replaced by alanine.
All mutants were generated by a megaprimed PCR-based
approach with a PM/Scl-75 cDNA as a template and specific
primers overlapping the regions that were mutated. The result-Page 2 of 9
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pCR4-TOPO (Invitrogen, Carlsbad, USA) or pCI-neo vector.
The integrity of the mutant constructs was confirmed by DNA
sequencing. The resulting cDNAs were used as templates for
in vitro transcription/translation of the respective proteins.
In vitro cleavage assay
Proteins were generated by in vitro transcription and transla-
tion with the TnT T7-coupled rabbit reticulocyte lysate system
(Promega) as described by the manufacturer. For detection of
the translation products, [35S]methionine was added to the
translation reactions. Proteins translated in vitro were incu-
bated with the purified murine recombinant caspases at 200
nM in a total volume of 25 μl of CFS buffer (220 mM mannitol,
68 mM sucrose, 2 mM NaCl, 2.5 mM KH2PO4, 10 mM
HEPES, pH 7.4, 1 mM aprotinin, 1 mM leupeptin, 1 mM phe-
nylmethylsulfonylfluoride, supplemented with 10 mM dithioth-
reitol) for 1.5 hours at 37°C. The resulting cleavage products
were analyzed by 10% SDS-PAGE and Western blotting fol-
lowed by autoradiography.
Results
Cleavage of PM/Scl-75 during apoptosis
To study the potential modification of human exosome compo-
nents during apoptosis, Jurkat cells were treated with the ago-
nistic anti-Fas antibody 7C11 and cell extracts were analyzed
by Western blotting with a patient's serum (Ven96) known to
be reactive with the major autoantigenic exosome components
PM/Scl-100, PM/Scl-75 and hRrp4p. The results of this anal-
ysis demonstrated that the intensity of the PM/Scl-75 band
was strongly reduced after the induction of apoptosis,
whereas the signals of PM/Scl-100 and hRrp4p were only
slightly diminished (data not shown). To analyze this phenom-
enon in more detail, a similar blot was analyzed with a rabbit
serum raised against PM/Scl-75 (Figure 1a). The result con-
firmed that most full-length PM/Scl-75 disappeared during
apoptosis, concomitant with the appearance of a faster-
migrating polypeptide at approximately 45 kDa (Figure 1a,
lane 3). To investigate whether the production of this putative
PM/Scl-75 cleavage fragment was indeed dependent on the
induction of apoptosis, the cleavage of PM/Scl-75 was ana-
lyzed in anti-Fas-stimulated normal Jurkat cells (Jurkat/Neo)
and Jurkat cells overexpressing Bcl-2 (Jurkat/Bcl-2). In the Jur-
kat/Bcl-2 cells the induction of apoptosis has been demon-
strated to be delayed considerably by preventing cytochrome
c release and caspase activation [15]. Indeed, the PM/Scl-75
cleavage product was produced in the Jurkat/Neo cells but
could not be detected in the Jurkat/Bcl-2 cells, not even after
8 hours of anti-Fas treatment (Figure 1b).
To investigate whether cleavage of PM/Scl-75 also occurred
in other cells and on exposure to other apoptotic stimuli, we
analyzed lysates of other cell lines as well as lysates from lym-
phocytes isolated from peripheral blood in which apoptosis
had been induced in various ways. CCRF-CEM cells were
exposed to actinomycin D, anisomycin, cycloheximide, stau-
rosporin or anti-Fas antibodies and Peer cells were cultured in
the presence of actinomycin D, anisomycin, cycloheximide or
staurosporin, and after 8 hours extracts of these cells were
analyzed by Western blotting (Figure 2). Except for the CCRF-
CEM cells treated with actinomycin D (lane 2) and with
cycloheximide (lane 4), a decrease in the full-length PM/Scl-75
signals and the appearance of the cleavage product of PM/
Scl-75 was detected in all lysates, indicating that PM/Scl-75
cleavage is a general phenomenon in apoptotic cells. As can
be seen in Figures 1 and 2, the anti-PM/Scl-75 rabbit serum
also showed reactivity with a number of as yet unidentified
proteins. Apoptotic modification of PM/Scl-75 was also
Figure 1
Cleavage of the PM/Scl-75 protein during anti-Fas-induced apoptosis. (a) Jurkat cells were treated with the anti-Fas monoclonal antibody 7C11 for 
the indicated durations. Protein extracts were analyzed by 10% SDS-PAGE and Western blotting with a polyclonal anti-PM/Scl-75 rabbit serum. (b) 
Jurkat/Neo and Jurkat/Bcl-2 cells were treated with the anti-Fas monoclonal antibody 7C11 for the indicated durations. Protein extracts were ana-
lyzed by 10% SDS-PAGE and Western blotting with the anti-PM/Scl-75 rabbit serum. In each panel the positions of molecular mass markers are 
indicated in kDa at the right and the positions of the relevant polypeptides are shown at the left. Filled arrowheads indicate full-length proteins, open 
arrowheads indicate cleavage products and the asterisk indicates a cross-reactivity of the anti-PM/Scl-75 serum with an unknown protein.Page 3 of 9
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with anti-Fas antibodies or ionomycin for 6 hours (data not
shown).
Association of the PM/Scl-75 cleavage fragment with 
the exosome complex
The most obvious explanation of the results described above
is that PM/Scl-75 is cleaved by a protease that is activated in
apoptotic cells, resulting in two proteolytic fragments.
Because the rabbit antiserum is reactive only with the 45 kDa
fragment, our data do not exclude the possibility that the other
fragment is further degraded. PM/Scl-75 is one of the core
components of the exosome complex, and most PM/Scl-75
molecules in a cell are believed to be associated with this com-
plex. To analyze whether the apoptotic cleavage fragment of
PM/Scl-75 can associate with the exosome complex, immuno-
precipitations were performed with extracts from control and
apoptotic Jurkat cells. The results in Figure 3 show that not
only anti-PM/Scl-75 rabbit serum and patient serum Ven96,
but also rabbit antibodies against hRrp46p, another exosome
core subunit, (co-)precipitated both the wild-type and the
cleaved PM/Scl-75 protein. Note that in this experiment PM/
Scl-75 was detected by a polyclonal mouse serum raised
against the recombinant protein. This result indicates that at
least a subset of cleaved PM/Scl-75 molecules either binds to
the exosome or remains associated with the core of the
exosome.
PM/Scl-75 cleavage is caspase mediated
Because the activation of caspases is a common feature of
apoptotic cells and because activated caspases are capable
of cleaving a large number of (autoantigenic) proteins, we
investigated whether caspase activation was required for
cleavage of PM/Scl-75. Jurkat cells were cultured in the pres-
ence of various inhibitors of caspases for 1 hour before the
induction of apoptosis by anti-Fas. Four different tetrapeptide
caspase inhibitors were used, namely Ac-YVAD-CMK for
group I caspases (caspase-1-like), Z-DEVD-FMK for group II
caspases (caspase-3-like), and Z-IETD-FMK (caspase-8) and
Z-LEHD-FMK (caspase-9) for group III caspases. Rabbit anti-
PM/Scl-75 antiserum was used to analyze the cleavage of PM/
Scl-75 in these cells. The cleavage of PM/Scl-75 was com-
pletely inhibited in the presence of 2 or 20 μM Ac-YVAD-CMK,
Z-DEVD-FMK or Z-IETD-FMK (Figure 4, lanes 4 to 9). In the
presence of Z-LEHD-FMK, PM/Scl-75 cleavage was partly
inhibited at 2 μM and completely inhibited in the presence of
a 10-fold higher concentration (Figure 4, lanes 10 and 11). As
a control for the inhibitory activity of the tetrapeptide inhibitors,
the cell extracts were also analyzed for cleavage of U1-70K
and Sm-F. The inhibition of cleavage of both caspase sub-
strates seemed to be very similar to that observed for PM/Scl-
75 (data not shown). These results suggest that caspases, or
other proteases activated downstream of the caspase cas-
cade, are involved in the apoptotic cleavage of PM/Scl-75.
Cleavage of PM/Scl-75 by different caspases
To determine whether PM/Scl-75 is a direct substrate for cas-
pases, PM/Scl-75 translated in vitro was incubated with
recombinant murine caspase-1, caspase-2, caspase-3,
caspase-7, caspase-8 and caspase-11. Four of these cas-
pases seemed to be able to cleave PM/Scl-75, resulting in
cleavage products similar in size to the fragment generated in
vivo (Figure 5a). However, the efficiencies by which this pro-
tein is cleaved by the recombinant caspases showed marked
differences. Caspase-1 very efficiently cleaved PM/Scl-75,
whereas decreasing efficiencies were observed for caspase-
8, caspase-7 and caspase-3. The recombinant caspase-2 and
caspase-11 did not result in detectable levels of PM/Scl-75
cleavage (Figure 5a, lanes 3 and 7). As a control for caspase
activity, all recombinant caspases were incubated with a spe-
cific fluorogenic substrate (Figure 5b). Because caspase-8
has a key role in apoptosis mediated by a death domain recep-
tor, we tested whether caspase-8 is essential for the cleavage
of PM/Scl-75 in apoptotic cells: caspase-8-deficient Jurkat
cells (ATCC CRL-2571) were used to analyze the apoptotic
processing of PM/Scl-75. These cells become apoptotic
when treated with staurosporin in combination with cyclohex-
imide. Despite the absence of caspase-8, on induction of
apoptosis the same cleavage pattern was observed as in con-
trol cells containing caspase-8 (data not shown). This sug-
gests that, in agreement with the proteolysis results in vitro,
other caspases contribute to the cleavage of PM/Scl-75 in
apoptotic cells.
Figure 2
Cleavage of the PM/Scl-75 protein in various cell types treated with dif-fer nt apoptosis inducers
ferent apoptosis inducers. CCRF-CEM cells were treated with actino-
mycin D (A), anisomycin (AN), cycloheximide (C), staurosporin (S) or 
anti-Fas mAb 7C11 (α-Fas); Peer cells were treated with actinomycin 
D (A), anisomycin (AN), cycloheximide (C) or staurosporin (S). Cell 
extracts were analyzed by 10% SDS-PAGE and Western blotting with 
the anti-PM/Scl-75 rabbit serum. Extracts from mock-treated cells were 
loaded in lanes 1 and 7. The positions of molecular mass markers are 
indicated in kDa at the right and the positions of the relevant polypep-
tides are shown at the left. Filled arrowheads indicate full-length pro-
teins and open arrowheads indicate cleavage products; the asterisk 
indicates a cross-reactivity with an unidentified protein.Page 4 of 9
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The association of the 45 kDa PM/Scl-75 fragment with the
exosome (see above) suggested that this fragment represents
the N-terminal part of the protein, because this region contains
the RNase PH domain, which is involved in the association
with the exosome complex [14]. Immunoprecipitations per-
formed with caspase-1-cleaved in vitro-translated PM/Scl-75
carrying a VSV-G tag at either the N or C terminus did indeed
show that the 45 kDa fragment could be precipitated only
when the VSV tag was attached to the N terminus of the pro-
tein (data not shown). These data indicate that the major cas-
pase cleavage site in PM/Scl-75 is located in the C-terminal
domain of the protein.
To determine the exact position of the cleavage site in PM/Scl-
75, substitution mutants were generated in which the aspartic
acid residues marked in Figure 6a were replaced by alanine
residues. Aspartic acid residues were chosen because each
of the caspases requires this amino acid at the cleavage site,
and thus replacement by alanine is expected to interfere with
cleavage. After incubation with the recombinant caspase-3 or
caspase-8, the specific cleavage product was no longer
observed with the PM/Scl-75 protein containing the substitu-
tion at position 369 (D369A) (Figure 6b, lanes 9 and 14),
whereas the other mutations did not influence the cleavage of
PM/Scl-75 by these caspases. In addition, when this mutant
was incubated with caspase-1 the cleavage of PM/Scl-75 was
Figure 3
The apoptotic cleavage product of PM/Scl-75 remains associated with the exosome. Immunoprecipitations from control (0 hours) and apoptotic (8 
hours incubated with anti-Fas antibody) Jurkat cell extracts were performed with normal rabbit serum (lanes 3 and 4), anti-PM/Scl-75 (lanes 5 and 6) 
and anti-hRrp46p (lanes 7 and 8) rabbit sera, and patient serum Ven96 (lanes 9 and 10). In lanes 1 and 2 input samples, 20% of the total control 
and apoptotic cell extracts, respectively, were loaded. Immunoprecipitates were analyzed by 10% SDS-PAGE and Western blotting with a polyclo-
nal anti-PM/Scl-75 mouse serum. The positions of the PM/Scl-75 protein (filled arrowhead), its cleavage product (open arrowhead) and a cross-
reactivity of the anti-PM/scl-75 serum (asterisk) are indicated at the left. The positions of molecular mass markers are indicated in kDa at the right.
Figure 4
Inhibition of PM/Scl-75 cleavage by caspase inhibitors i i it r . Jurkat cells were cultured for 1 hour at 37°C in the presence of four cell-permeable tetrapep-
tide caspase inhibitors: 2 μM (lanes 4, 6, 8 and 10) or 20 μM (lanes 5, 7, 9 and 11) inhibitors of caspase-1 (YVAD), caspase-3 (DEVD), caspase-8 
(IETD) and caspase-9 (LEHD). Subsequently, cells were cultured for 8 hours in the presence of anti-Fas monoclonal antibody (α-Fas). Control 
extract from mock-treated Jurkat cells was loaded in lane 1. In lanes 2 and 3 extracts from control and apoptotic (8 hours anti-Fas mAb) Jurkat cells, 
respectively, were analyzed. Total protein extracts were analyzed by 10% SDS-PAGE and Western blotting with the anti-PM/Scl-75 rabbit serum. 
The positions of molecular mass markers are indicated in kDa at the right and the positions of the relevant polypeptides at the left. Filled arrowheads 
indicate full-length proteins, open arrowheads indicate cleavage products and the asterisk indicates cross-reactivity of the anti-PM/Scl-75 serum.Page 5 of 9
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Cleavage of PM/Scl-75 by recombinant caspases. (a) 35S-labeled PM/Scl-75 translated in vitro was incubated with 200 nM purified murine recom-
binant caspase-1, caspase-2, caspase-3, caspase-7, caspase-8 or caspase-11 for 1.5 hours at 37°C. The resulting reaction products were analyzed 
by 10% SDS-PAGE, followed by autoradiography. In the first lane the mock-incubated protein was loaded. The filled arrowhead marks the full-length 
proteins and the open arrowhead the cleavage products. Note that in this experiment the pCI-neo-VSV-PM/Scl-75c-α cDNA was used for in vitro 
transcription and translation of PM/Scl-75. The positions of molecular mass markers are indicated in kDa at the right and the positions of the relevant 
polypeptides at the left. (b) As a control for caspase activity the recombinant caspases were incubated with 50 μM fluorogenic substrate in 200 μl 
of CFS buffer. The release of fluorescent 7-amino-4-methylcoumarin was monitored for 1 hour at 37°C at 2-minute intervals in a fluorimeter. Data are 
expressed as the increase in fluorescence (Delta F) as a function of time.Page 6 of 9
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gest that the IILD369↓G sequence represents the caspase
cleavage site in the PM/Scl-75 protein during apoptosis.
Discussion
Although many different autoantibodies have been identified in
a variety of autoimmune diseases, the mechanism that leads to
the production of most of these autoreactive antibodies is still
unknown. During the past decade a substantial number of
autoantigens have been shown to be modified during apopto-
sis and/or necrosis. This has led to the hypothesis that intrac-
ellular, modified autoantigens are exposed to the immune
system because of massive cell death and/or inefficient
removal of dying cells, which could elicit a primary immune
Figure 6
Mapping of the caspase cleavage site in PM/Scl-75. (a) Amino acid sequence of PM/Scl-75 (α variant). The RNase pleckstrin homology (PH) 
domain, the nuclear localization signal, the N termini of both published sequences, PM/Scl-75a [13] and PM/Scl-75c [14], and the position (aster-
isk) where the β splice variant contains a 17-amino-acid insertion are indicated. Note that the numbering of the amino acid positions corresponds to 
that of PM/Scl-75c-α. All aspartic acid residues that were replaced by alanines are highlighted in black. The mutants that were used in the experi-
ment shown in (b) are marked by arrows (D349A, D363A and D374A) and the identified cleavage site by arrowheads (D369A). (b) Cleavage of PM/
Scl-75 mutants by recombinant caspases. In vitro translated 35S-labeled PM/Scl-75c-α and mutants of the protein in which the aspartic acid resi-
dues at positions 347 (D347A), 363 (D363A), 368 (D369A) or 374 (D374A) were changed into alanine residues were incubated with purified 
murine recombinant caspase-3 or caspase-8 for 1.5 hours at 37°C. The resulting reaction products were analyzed by SDS-PAGE followed by auto-
radiography. In lanes 1 to 5 the proteins incubated in parallel in the absence of caspases were loaded (control). The positions of molecular mass 
markers are indicated in kDa at the right, and the positions of relevant polypeptides are shown at the left. Filled arrowheads indicate full-length PM/
Scl-75c-α and open arrowheads indicate the PM/Scl-75 cleavage product. Note that in this experiment the pCR4-TOPO-PM/Scl-75c-α cDNA [14] 
was used for the transcription and translation of PM/Scl-75 in vitro. As a result of translation initiation at an internal start codon in the reticulocyte 
lysate, a relatively high level of a second polypeptide was produced, which was shown to represent a polypeptide initiated at Met85, thus corre-
sponding to PM/Scl-75a-α. WT, wild type.Page 7 of 9
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secondary response, other parts of the autoantigenic molecule
or its interacting partners might also be targeted by the
immune system as a result of epitope spreading [1]. Patients
with the PM/Scl overlap syndrome often develop antibodies
against several components of the human PM/Scl or exosome
complex, especially against PM/Scl-100, PM/Scl-75 and
hRrp4p [19]. Here we show for the first time that one of the
exosome subunits, PM/Scl-75, is specifically modified during
apoptosis. The generation of a PM/Scl-75 fragment in apop-
totic lysates of caspase-8-deficient Jurkat cells, the results
from the caspase inhibitor studies in anti-Fas-treated cells, and
the cleavage of PM/Scl-75 by different caspases in vitro
resulting in a similar cleavage pattern all suggest that several
caspases are implicated in the proteolytic cleavage of PM/Scl-
75. However, we cannot exclude the possibility that cleavage
of PM/Scl-75 is not performed directly by caspases and is
instead an indirect effect of the activation of other proteases
during apoptosis. The cleavage of PM/Scl-75 occurs in the C-
terminal part of the protein at the unconventional caspase
cleavage site IILD369↓G. However, cleavage of other autoanti-
gens such as DNA topoisomerase I and Sm-F have also been
reported to be cleaved by caspases at unconventional sites
[16,20,21].
Consistent with the observation that the C-terminal part of the
protein is cleaved during apoptosis, leaving the RNase PH
domain intact, is our finding that a subset of cleaved PM/Scl-
75 molecules remains associated with the core of the exo-
some complex (Figure 3). A very similar situation has been
described for the Sm-F protein, which is cleaved apoptotically
while remaining associated with the heptameric ring of the Sm
complex [16]. On the basis of interactions between exosome
components and structural similarity with the bacterial protein
polynucleotide phosphorylase, a model was generated for the
structure of the human exosome. In this model the six proteins
containing an RNase PH domain form the core of the exo-
some, which adopts a hexameric ring structure [22]. This
model is strongly supported by the crystal structures of the
archaeal, yeast and human exosome [23-26]. Interestingly, the
crystal structure of the human exosome shows that the C-ter-
minal extension of PM/Scl-75 interacts with hRrp46 and
wraps around both hRrp46 and OIP2 (hRrp43) on the outer
surface of the ring, demonstrating that the identified cleavage
site of PM/Scl-75, which is located in the middle of this exten-
sion, is accessible to caspases. The observation that PM/Scl-
75 is cleaved during apoptosis might also have implications
for the activity and function of the exosome complex.
Recently, it has been reported that the activity of the human
exosome is restricted to the hRrp41p–PM/Scl-75 het-
erodimer. As a consequence, cleavage of PM/Scl-75 may
influence the catalytic activity of the complex [26]. Moreover, it
has been shown that PM/Scl-75 contains a nuclear localiza-
tion signal, which has a role in the nucleolar targeting of PM/
Scl-75 [14]. The cleavage of PM/Scl-75 in apoptotic cells
removes the nuclear localization signal from the protein, which
may change the subcellular distribution of the protein and the
associated complex, as has been reported for the La autoanti-
gen [27]. It is therefore tempting to speculate that cleavage of
PM/Scl-75 leads to an increased exosome concentration in
the cytoplasm and/or in the nucleoplasm, which may be
required for an enhanced degradation rate of a variety of RNA
molecules in these compartments during apoptosis. Simulta-
neously, cleavage of PM/Scl-75 would result in the release of
the exosome from the nucleolus, leading to a loss of exosome
function in this cellular compartment.
As described above, recent studies have led to the hypothesis
that cell-death-induced modifications can generate neo-
epitopes that trigger an autoimmune response. If the immune
system is exposed to elevated and persistent levels of apop-
totically modified PM/Scl-75, this could contribute to breaking
the immunological tolerance to the exosome complex, leading
to the production of autoantibodies against components of
this complex. It would therefore be interesting to investigate
whether the B-cell repertoires of PM/Scl patients in the early
phase of the disease contain antibodies that are specifically
reactive with the apoptotic PM/Scl-75 protein fragment. Such
autoantibodies that preferentially recognize apoptotically mod-
ified isoforms of the autoantigen have been shown to exist for
the U1-70K protein [28,29].
Conclusion
This study shows that the autoantigenic exosome component
PM/Scl-75 is specifically cleaved during apoptosis. A 45 kDa
fragment of PM/Scl-75 is generated in apoptotic Jurkat cells.
This fragment, which corresponds to the N-terminal part of
PM/Scl-75, is associated at least in part with the exosome
complex. Cleavage assays in vitro with different recombinant
caspases suggest that several caspases might be responsible
for the proteolytic cleavage of PM/Scl-75, although caspase-
1 seems to be the most effective. The caspase cleavage site
was mapped in the C-terminal part of the protein at Asp369
(IILD369↓G).
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